A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
The purpose of the study is to find out whether treatment with daratumumab and lenalidomide improves disease response in multiple myeloma. You will receive either lenalidomide alone, or both lenalidomide and daratumumab. A computer will by chance assign you to treatment groups in the study. This is called randomization. You will have a 50% chance of being in either group.
- Men and women 18-79 years of age with newly diagnosed multiple myeloma who are Minimal Residual Disease positive after frontline autologous stem cell transplant (ASCT)
- You must not have had prior treatment with an anti-CD38 antibody, such as daratumumab
18 - 79
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug(s) until your disease gets worse, the side effects become too severe, or you complete 36 cycles (about 3 years). After you finish the study drug(s), the investigator will continue to watch you for side effects and follow your condition for up to 4 years.
Clinical Trials Information Line
Janssen Research & Development, LLC.